The findings suggest that sustained activation of the Jagged-1/Notch signaling in gastric cancer cells elicits an aberrant release of IL-6, leading to the transition of survival signaling, phenotype conversion, and resistance to trastuzumab. Here, IL6 is linked to gastric cancer.